• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Sitryx appoints Adam Mostafa as Chief Financial Officer

    9/8/25 7:00:00 AM ET
    $ABP
    $CPIX
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABP alert in real time by email

    Sitryx appoints Adam Mostafa as Chief Financial Officer

    • Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership



    Oxford, UK and Boston, MA – 8 September 2025 – Sitryx Therapeutics ("the Company"), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announces the appointment of Adam Mostafa as Chief Financial Officer (CFO), effective today.

    With over 25 years of experience, Adam is a seasoned biotech executive and financial leader. He joins Sitryx with a distinguished background spanning across biotech and healthcare financial sectors, where he has raised over $1 billion in institutional capital and secured multiple strategic partnerships, while helping to lead companies from early-stage clinical efforts to approval and commercialization. Most recently, Adam served as CFO for X4 Pharmaceuticals (NASDAQ:XFOR), where he played a pivotal role in driving the company's financial and growth strategies, including the close of X4's reverse merger with Arsanis in 2019 and subsequent Nasdaq public listing, and the FDA approval and commercial launch of XOLREMDI®, a novel rare disease therapeutic. Prior to this, he held the role of CFO at Abpro Holdings (NASDAQ:ABP). He currently sits on the Board of Satellos Bioscience (TSX:MSCL) and Precision Biologics and is a Senior Advisor to Cumberland Pharmaceuticals (NASDAQ:CPIX).

    Adam's earlier career featured significant tenures at major financial institutions including Managing Director in the healthcare investment banking group at Cantor Fitzgerald, Senior Banker at Needham & Company, Vice President at CRT Capital Group and Portfolio Management Associate at AQR Capital. He holds a Bachelor's degree in Economics from Brown University.

    Iain Kilty, Chief Executive Officer of Sitryx, commented: "We are delighted to welcome Adam to Sitryx. His extensive financial expertise, strategic leadership, and broad experience across the healthcare sector will be invaluable as we enter our next phase of growth. With a proven track record of guiding innovative biotech companies, his appointment strengthens our position as we advance the development of our proprietary clinical-stage pipeline of small molecules for the treatment of chronic autoimmune and inflammatory diseases."

    Adam Mostafa, incoming Chief Financial Officer, added: "I am thrilled to be joining Sitryx at such a pivotal stage in its journey. The team has built an impressive foundation with a highly innovative clinical pipeline that has the potential to change the treatment paradigm of multiple chronic autoimmune and inflammatory diseases. I look forward to working closely with the team to further drive the Company's growth and deliver on its potential to make a significant impact on patients' lives."

    -Ends-

    For more information about Sitryx please contact:

    ICR Healthcare

    Mary-Jane Elliott, David Daley

    +44 (0)20 3709 5700

    [email protected]

    About Sitryx

    Sitryx is a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease. The Company has a broad pipeline of novel small molecule candidates targeting major autoimmune indications with high unmet need. Its lead candidate, SYX-5219, is a potentially first-in-class PKM2 modulator in development for atopic dermatitis as a once-daily oral therapy with future development potential across multiple autoimmune diseases.

    Established in 2018 with seed funding from SV Health Investors, Sitryx has raised $85 million to date from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Oxford Science Enterprises, Longwood Fund, Eli Lilly and Company, and GSK.

    Sitryx is headquartered in Oxford, UK. For more information, please visit www.sitryx.com.



    Primary Logo

    Get the next $ABP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABP
    $CPIX
    $XFOR

    CompanyDatePrice TargetRatingAnalyst
    X4 Pharmaceuticals Inc.
    $XFOR
    12/12/2023$3.00 → $1.00Buy → Neutral
    B. Riley Securities
    X4 Pharmaceuticals Inc.
    $XFOR
    8/30/2023$3.00Buy
    B. Riley Securities
    X4 Pharmaceuticals Inc.
    $XFOR
    12/22/2022$3.00Overweight
    Cantor Fitzgerald
    X4 Pharmaceuticals Inc.
    $XFOR
    12/12/2022$3.00Overweight
    Piper Sandler
    X4 Pharmaceuticals Inc.
    $XFOR
    12/14/2021$21.00 → $11.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ABP
    $CPIX
    $XFOR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XOLREMDI issued to X4 PHARMACEUTICALS INC

    Submission status for X4 PHARMACEUTICALS INC's drug XOLREMDI (ORIG-1) with active ingredient MAVORIXAFOR has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218709, Application Classification: Type 1 - New Molecular Entity

    4/29/24 2:36:51 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABP
    $CPIX
    $XFOR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Young Caroline bought $398 worth of shares (121 units at $3.29), increasing direct ownership by 0.37% to 32,942 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    9/12/25 8:36:28 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jones James bought $862 worth of shares (262 units at $3.29), increasing direct ownership by 0.60% to 43,938 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    9/12/25 8:35:26 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman and CEO Kazimi A J bought $862 worth of shares (262 units at $3.29), increasing direct ownership by 0.00% to 5,700,030 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    9/12/25 8:34:18 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABP
    $CPIX
    $XFOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    X4 Pharmaceuticals downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded X4 Pharmaceuticals from Buy to Neutral and set a new price target of $1.00 from $3.00 previously

    12/12/23 8:15:43 AM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities resumed coverage on X4 Pharmaceuticals with a new price target

    B. Riley Securities resumed coverage of X4 Pharmaceuticals with a rating of Buy and set a new price target of $3.00

    8/30/23 7:46:17 AM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on X4 Pharmaceuticals with a new price target

    Cantor Fitzgerald initiated coverage of X4 Pharmaceuticals with a rating of Overweight and set a new price target of $3.00

    12/22/22 7:56:33 AM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABP
    $CPIX
    $XFOR
    SEC Filings

    View All

    SEC Form 424B3 filed by X4 Pharmaceuticals Inc.

    424B3 - X4 Pharmaceuticals, Inc (0001501697) (Filer)

    9/18/25 4:19:13 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by Abpro Holdings Inc

    DEFA14A - Abpro Holdings, Inc. (0001893219) (Filer)

    9/18/25 4:15:18 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by X4 Pharmaceuticals Inc.

    EFFECT - X4 Pharmaceuticals, Inc (0001501697) (Filer)

    9/18/25 12:15:16 AM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABP
    $CPIX
    $XFOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Young Caroline bought $398 worth of shares (121 units at $3.29), increasing direct ownership by 0.37% to 32,942 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    9/12/25 8:36:28 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jones James bought $862 worth of shares (262 units at $3.29), increasing direct ownership by 0.60% to 43,938 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    9/12/25 8:35:26 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman and CEO Kazimi A J bought $862 worth of shares (262 units at $3.29), increasing direct ownership by 0.00% to 5,700,030 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    9/12/25 8:34:18 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABP
    $CPIX
    $XFOR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO

    Injectable Ibuprofen Approved for Treating Pain & Fever NASHVILLE, Tenn., Oct. 1 , 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced that its ibuprofen injection product, has received regulatory approval in Mexico. The approval follows Cumberland's partnership with PiSA Farmaceutica, which includes exclusive supply and distribution rights for the ibuprofen product in the Mexican market. PiSA is a well-established Mexican pharmaceutical firm with a leading injectable business in that country. Under the agreem

    10/1/25 9:05:00 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA

    Vibativ® treats patients with pneumonia and serious skin infections NASHVILLE, Tenn. and RIYADH, Saudi Arabia, Sept. 29, 2025 /PRNewswire/ -- Specialty pharmaceutical companies Tabuk Pharmaceutical Manufacturing Company a fully owned subsidiary of Astra Industrial Group and a leading pharmaceutical company in the Middle East and Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the launch of Cumberland's Vibativ® (telavancin) injection in Saudi Arabia. The announcement follows an agreement between the companies providing Tabuk

    9/29/25 9:05:00 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

    Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises GAITHERSBURG, Md., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Christophe Arbet-Engels, MD, PhD as Chief Medical Officer, effective October 1, 2025. Dr. Arbet-Engels joins the Company with more than 30 years of experience spanning industry, academia and private practice, and will lead the ongoing c

    9/29/25 7:30:11 AM ET
    $ALT
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ABP
    $CPIX
    $XFOR
    Leadership Updates

    Live Leadership Updates

    View All

    Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

    Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises GAITHERSBURG, Md., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Christophe Arbet-Engels, MD, PhD as Chief Medical Officer, effective October 1, 2025. Dr. Arbet-Engels joins the Company with more than 30 years of experience spanning industry, academia and private practice, and will lead the ongoing c

    9/29/25 7:30:11 AM ET
    $ALT
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Sitryx appoints Adam Mostafa as Chief Financial Officer

    Sitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK and Boston, MA – 8 September 2025 – Sitryx Therapeutics ("the Company"), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announces the appointment of Adam Mostafa as Chief Financial Officer (CFO), effective today. With over 25 years of experience, Adam is a seasoned biotech executive and financial leader. He joins Sitryx with a distinguished background spanning across biotech and healthcare financial

    9/8/25 7:00:00 AM ET
    $ABP
    $CPIX
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Abpro Statement on the Departure of Former CEO Ian Chan

    WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases announced today the departure of Chief Executive Officer Ian Chan. Commenting on the leadership change, Abpro Board Chairman and CEO Miles Suk, said, "As disclosed in our regulatory filing on Friday, the Board has decided to part ways with Ian Chan. I want to thank Ian for his service and wish him well. This leadership transition, however, does not affect our stability or direction. Instead, it marks the first step toward a stronger, more promising future. We remain fully co

    3/10/25 6:34:55 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABP
    $CPIX
    $XFOR
    Financials

    Live finance-specific insights

    View All

    CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO

    Injectable Ibuprofen Approved for Treating Pain & Fever NASHVILLE, Tenn., Oct. 1 , 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced that its ibuprofen injection product, has received regulatory approval in Mexico. The approval follows Cumberland's partnership with PiSA Farmaceutica, which includes exclusive supply and distribution rights for the ibuprofen product in the Mexican market. PiSA is a well-established Mexican pharmaceutical firm with a leading injectable business in that country. Under the agreem

    10/1/25 9:05:00 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA

    Vibativ® treats patients with pneumonia and serious skin infections NASHVILLE, Tenn. and RIYADH, Saudi Arabia, Sept. 29, 2025 /PRNewswire/ -- Specialty pharmaceutical companies Tabuk Pharmaceutical Manufacturing Company a fully owned subsidiary of Astra Industrial Group and a leading pharmaceutical company in the Middle East and Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the launch of Cumberland's Vibativ® (telavancin) injection in Saudi Arabia. The announcement follows an agreement between the companies providing Tabuk

    9/29/25 9:05:00 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date

    NASHVILLE, Tenn., Aug. 5, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $10.8 million during the second quarter of 2025, a 10% increase over the prior year period. Year-to-date revenues for the first six months of the year totaled $22.6 million, representing an increase of 23% over the first half of 2024. Cumberland ended the quarter with approximately $68 million in total assets, $40 million in liabilities and $28 milli

    8/5/25 4:05:00 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABP
    $CPIX
    $XFOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by X4 Pharmaceuticals Inc.

    SC 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)

    11/12/24 5:59:35 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by X4 Pharmaceuticals Inc.

    SC 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)

    11/4/24 2:15:54 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by X4 Pharmaceuticals Inc. (Amendment)

    SC 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)

    2/14/24 7:36:59 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care